MLTX Stock Overview
A clinical-stage biopharmaceutical company, engages in developing therapies.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MoonLake Immunotherapeutics Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.16 |
| 52 Week High | US$64.98 |
| 52 Week Low | US$35.11 |
| Beta | 1.25 |
| 11 Month Change | 7.57% |
| 3 Month Change | 15.49% |
| 1 Year Change | -10.03% |
| 33 Year Change | 387.45% |
| 5 Year Change | n/a |
| Change since IPO | 359.10% |
Recent News & Updates
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27
MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14Recent updates
MoonLake Immunotherapeutics (NASDAQ:MLTX) Is In A Strong Position To Grow Its Business
Aug 27MoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab Forward
Jul 18Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
May 14MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3
Feb 26We're Not Worried About MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn
Jan 29Here's Why We're Not At All Concerned With MoonLake Immunotherapeutics' (NASDAQ:MLTX) Cash Burn Situation
Oct 16Vetter Pharma to provide fill and finish services to MoonLake Immunotherapeutics
Jul 26Shareholder Returns
| MLTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | 0.7% | 0.1% |
| 1Y | -10.0% | 15.8% | 24.9% |
Return vs Industry: MLTX underperformed the US Biotechs industry which returned 15.9% over the past year.
Return vs Market: MLTX underperformed the US Market which returned 25.9% over the past year.
Price Volatility
| MLTX volatility | |
|---|---|
| MLTX Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MLTX has not had significant price volatility in the past 3 months.
Volatility Over Time: MLTX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 50 | Jorge da Silva | www.moonlaketx.com |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics Fundamentals Summary
| MLTX fundamental statistics | |
|---|---|
| Market cap | US$3.13b |
| Earnings (TTM) | -US$54.80m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-55.3x
P/E RatioIs MLTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$54.80m |
| Earnings | -US$54.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLTX perform over the long term?
See historical performance and comparison